Eiger Biopharmaceuticals (EIGR) Getting Somewhat Favorable Press Coverage, Report Shows

News stories about Eiger Biopharmaceuticals (NASDAQ:EIGR) have been trending somewhat positive on Sunday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.9183280364726 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

EIGR stock traded down $1.20 during trading hours on Friday, hitting $9.10. The company’s stock had a trading volume of 64,458 shares, compared to its average volume of 68,335. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $95.80, a price-to-earnings ratio of -1.87 and a beta of 1.58. Eiger Biopharmaceuticals has a 12 month low of $6.10 and a 12 month high of $16.20.

How to Become a New Pot Stock Millionaire

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Monday, March 12th. The biotechnology company reported ($1.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.02) by ($0.09). research analysts expect that Eiger Biopharmaceuticals will post -4.22 EPS for the current fiscal year.

Several research analysts have weighed in on EIGR shares. ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Ladenburg Thalmann started coverage on shares of Eiger Biopharmaceuticals in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $32.00 price objective on the stock. Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Tuesday, January 9th. Piper Jaffray reissued an “overweight” rating and issued a $17.00 target price (down from $35.00) on shares of Eiger Biopharmaceuticals in a research report on Tuesday, January 16th. Finally, Oppenheimer set a $26.00 target price on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $27.25.

In other Eiger Biopharmaceuticals news, insider Joanne Quan sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $10.00, for a total value of $40,000.00. Following the completion of the sale, the insider now directly owns 4,000 shares of the company’s stock, valued at $40,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.80% of the company’s stock.

WARNING: “Eiger Biopharmaceuticals (EIGR) Getting Somewhat Favorable Press Coverage, Report Shows” was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3341651/eiger-biopharmaceuticals-eigr-getting-somewhat-favorable-press-coverage-report-shows.html.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.

Insider Buying and Selling by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Expect Qorvo  Will Post Quarterly Sales of $656.56 Million
Zacks: Analysts Expect Qorvo Will Post Quarterly Sales of $656.56 Million
$28.23 Million in Sales Expected for FibroGen  This Quarter
$28.23 Million in Sales Expected for FibroGen This Quarter
vTv Therapeutics  Expected to Post Quarterly Sales of $3.14 Million
vTv Therapeutics Expected to Post Quarterly Sales of $3.14 Million
Netko  Price Tops $0.19 on Top Exchanges
Netko Price Tops $0.19 on Top Exchanges
Onix  Reaches Market Capitalization of $324,379.00
Onix Reaches Market Capitalization of $324,379.00
Somewhat Favorable Press Coverage Somewhat Unlikely to Affect China Eastern Airlines  Share Price
Somewhat Favorable Press Coverage Somewhat Unlikely to Affect China Eastern Airlines Share Price


Leave a Reply

© 2006-2018 Ticker Report. Google+.